Skip to Main content Skip to Navigation
Journal articles

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape

Loria Zalmaï 1 Pierre-Julien Viailly 2 Sabeha Biichle 3 Meyling Cheok 4 Lou Soret 3 Fanny Angelot-Delettre 3 Tony Petrella 5 Marie-Agnès Collonge-Rame 6 Estelle Seilles 3 Sandrine Geffroy 4 Eric Deconinck 6 Etienne Daguindau 6 Sabrina Bouyer 7 Elodie Dindinaud 7 Victor Baunin 8 Magali Le Garff-Tavernier 9 Damien Roos-Weil 10 Orianne Wagner-Ballon 11 Véronique Salaun 12 Jean Feuillard 13 Sophie Brun 14 Bernard Drenou 15 Caroline Mayeur-Rousse 16 Patricia Okamba 17 Véronique Dorvaux 17 Michel Tichionni 18 Johann Rose 19 Marie-Thérèse Rubio 20, 21 Marie Christine Jacob 22 Victoria Raggueneau 23 Claude Preudhomme 4 Philippe Saas 3 Christophe Ferrand 3 Olivier Adotevi 3 Christophe Roumier 4 Fabrice Jardin 2 Francine Garnache-Ottou 3 Florian Renosi 3
Abstract : Neoplasms involving plasmacytoid Dendritic Cells (pDCs) include Blastic pDC Neoplasms (BPDCN) and other pDC proliferations, where pDCs are associated with myeloid malignancies: most frequently Chronic MyeloMonocytic Leukemia (CMML) but also Acute Myeloid Leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDCs in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DCs (cDCs) associated in the same sample, by phenotypic and molecular analyses (targeted NGS, 70 genes). We compared 15 pDC-AML at diagnosis with 21 BPDCN and 11 normal pDCs from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDCs (4-36%), monocytes in 14 cases (1-10%) and cDCs (2 cases, 4.8-19%). pDCs in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56- in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of cTCL1 and CD123 with isolated lymphoid markers (CD22/CD7/CD5) in some cases, suggesting a pre-pDC stage. In all cases, pDCs, monocytes and cDC are neoplastic since they harbor the same mutations as CD34+ blasts. RUNX1 is the most commonly mutated gene: detected in all AML with minimal differentiation (M0-AML) but not in the other cases. Despite low number of cases, the systematic association between M0-AML, RUNX1 mutations and an excess of pDC is puzzling. Further evaluation in a larger cohort is required to confirm RUNX1 mutations in pDC-AML with minimal differentiation and to investigate whether it represents a proliferation of blasts with macrophage and DC progenitor potential.
Complete list of metadata
Contributor : Marie Therese Rubio Connect in order to contact the contributor
Submitted on : Friday, May 14, 2021 - 6:34:58 PM
Last modification on : Monday, December 6, 2021 - 10:46:19 AM

Links full text



Loria Zalmaï, Pierre-Julien Viailly, Sabeha Biichle, Meyling Cheok, Lou Soret, et al.. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica, Ferrata Storti Foundation, 2020, ⟨10.3324/haematol.2020.253740⟩. ⟨hal-03226572⟩



Record views